$3.50
7.41% today
NYSE, Apr 03, 06:50 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$3.78
+0.78 26.00% 1M
+0.75 24.75% 6M
+0.00 0.00% YTD
+1.16 44.27% 1Y
-10.12 72.81% 3Y
-14.29 79.08% 5Y
-14.29 79.08% 10Y
NYSE, Closing price Wed, Apr 02 2025
+0.44 13.17%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $334.92m
Enterprise Value $160.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.84
P/S ratio (TTM) P/S ratio 3.83
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth -77.06%
Revenue (TTM) Revenue $87.37m
EBIT (operating result TTM) EBIT $-255.68m
Free Cash Flow (TTM) Free Cash Flow $-167.80m
Cash position $176.50m
EPS (TTM) EPS $-4.43
Short interest 4.55%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amylyx Pharmaceuticals forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
87 87
77% 77%
100%
- Direct Costs 126 126
373% 373%
144%
-38 -38
111% 111%
-44%
- Selling and Administrative Expenses 113 113
39% 39%
130%
- Research and Development Expense 103 103
19% 19%
118%
-255 -255
739% 739%
-292%
- Depreciation and Amortization 0.90 0.90
17% 17%
1%
EBIT (Operating Income) EBIT -256 -256
759% 759%
-293%
Net Profit -302 -302
712% 712%
-345%

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
Business Wire
one day ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference.
Neutral
Seeking Alpha
about one month ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Josh Cohen - Co-CEO Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Joe Beatty - Baird Operator Good...
Neutral
Business Wire
about one month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 123
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today